MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
3.490
-0.210
-5.68%
After Hours: 3.490 0 0.00% 16:10 05/15 EDT
OPEN
3.700
PREV CLOSE
3.700
HIGH
3.700
LOW
3.438
VOLUME
13.24K
TURNOVER
--
52 WEEK HIGH
56.80
52 WEEK LOW
3.015
MARKET CAP
3.99M
P/E (TTM)
-0.1697
1D
5D
1M
3M
1Y
5Y
1D
Why Akari Therapeutics Stock Is Surging On Thursday?
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 4d ago
Akari Therapeutics secures European patent for Thailanstatin-based payloads
TipRanks · 4d ago
Akari Therapeutics wins European patent for thailanstatin-based ADC payloads
PUBT · 4d ago
Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology
Benzinga · 4d ago
AKARI THERAPEUTICS PLC - AKTX-101 PHASE 1 FIRST-IN-HUMAN TRIAL TARGETED BY MID-2027
Reuters · 4d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4d ago
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.